Tampa, FL Clinical Trials Report — June 2026

For Tampa residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, with 67 clinical trials set to conclude enrollment within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Across Tampa, FL, there are currently 1,032 clinical trials recruiting participants at 428 research facilities. This month saw the opening of 13 new trials, a slight decrease from the 14 trials that launched in May 2026, but still offering fresh opportunities for engagement.

New Avenues for Medical Advancement

June brings several high-profile new trials to Tampa, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily for chronic weight management.
• Revolution Medicines, Inc. is leading NCT07621718, "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )." This Phase 3 study, targeting 670 participants, evaluates an investigational RAS(ON) inhibitor in combination with chemotherapy for metastatic pancreatic adenocarcinoma.
• PleoPharma, Inc. is sponsoring NCT07644052, "Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder." This Phase 3 randomized, double-blind, placebo and active-controlled trial seeks 420 participants to evaluate PP-01 in mitigating withdrawal symptoms from cannabis use disorder.
• Tonix Pharmaceuticals, Inc. is conducting NCT07621237, "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)." This Phase 2 study aims for 360 participants to assess the efficacy and safety of TNX-102 SL for moderate to severe major depressive disorder.
• Evommune, Inc. is leading NCT07616128, "Study of EVO756 in Adults With Migraine." This Phase 2 study will evaluate the efficacy and safety of EVO756 against placebo in 330 adults with migraine.
• Axsome Therapeutics, Inc. is sponsoring NCT07637162, "Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia." This Phase 3, multi-center, 52-week, open-label trial will evaluate the long-term safety and efficacy of AXS-14 in the management of fibromyalgia, involving 300 participants.

The 13 new trials this month are exploring a range of conditions. The most frequent conditions for new trials include pancreatic ductal adenocarcinoma (2 trials) and migraine (2 trials). Other new studies focus on breast cancer, cannabis withdrawal, chronic weight management, depression, fibromyalgia, G12D mutated KRAS, and healthy adults. Of the new trials, 12 are drug trials, 1 is a combination product, 1 is a device trial, and 1 falls under an 'other' category.

Urgent Opportunities: Trials Closing Soon

For those interested in trials with limited enrollment time, several conditions are highlighted among the 67 studies closing within 90 days. These include:

• Cancer (3 trials)
• Melanoma Stage IV (2 trials)
• Melanoma Stage III (2 trials)
• Pancreatic Cancer (2 trials)
• Systemic Lupus Erythematosus (2 trials)
• Ovarian Cancer (2 trials)
• COPD (2 trials)
• Major Depressive Disorder (2 trials)
• Asthma (1 trial)
• Bladder Pain Syndrome (1 trial)

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. 2 of the 13 new trials launched this month are actively seeking healthy volunteers. Across Tampa, a total of 56 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Tampa's Leading Research Facilities

Tampa is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Moffitt Cancer Center (281 trials)
• University of South Florida (106 trials)
• Tampa General Hospital (61 trials)
• Saint Joseph's Hospital/Children's Hospital-Tampa (39 trials)
• Research Site (35 trials)
• Moffitt Cancer Center - McKinley Campus (27 trials)
• Moffitt Cancer Center-International Plaza (24 trials)
• Moffit Cancer Center (9 trials)
• St. Joseph's Children's Hospital (8 trials)
• USF Health (8 trials)
• Neurocrine Clinical Site (8 trials)
• Clinical Site (8 trials)

These institutions offer a broad spectrum of research, with Moffitt Cancer Center specializing in oncology, and the University of South Florida and Tampa General Hospital covering diverse medical fields.

Broadening Your Search: Nearby Options

While Tampa offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Miami (24 trials), Jacksonville (17 trials), Orlando (16 trials), Maitland (8 trials), Ocala (7 trials), Leesburg (6 trials), Ocoee (5 trials), and Hollywood (5 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 13 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is female-only. Industry sponsors like Gasherbrum Bio, Inc., Revolution Medicines, Inc., PleoPharma, Inc., Tonix Pharmaceuticals, Inc., Evommune, Inc., and Axsome Therapeutics, Inc. are driving significant research efforts this month.

As we move through June, Tampa's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.